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Abstract
Background: Noninvasive T2* magnetic resonance imaging (MRI) assessment can stratify the risk of subsequent cardiac dysfunction 
in β-thalassemia major (TM) and β-thalassemia intermedia (TI) patients. The normal level of N-terminal pro B-type natriuretic peptides 
(NT-proBNP) can rule out acute heart failure. Aim: We aim to investigate the relation of NT-proBNP level, T2* MRI, and echocardiographic 
findings in TM and TI patients. Materials and methods: In this cross-sectional study, 41 TM patients, 41 TI patients, and 41 healthy indi-
viduals (HI) were enrolled. NT-proBNP level, T2* MRI, and two-dimensional echocardiography were assessed for all patients and con-
trols. Results: There was statistically significant correlation between NT-proBNP levels and mitral inflow late diastolic velocity (r = -0.538; 
p = 0.006) in TM group. There was statistically significant correlation between NT-proBNP levels and tricuspid annulus systolic velocity 
(r = -0.438; p = 0.028), systolic velocity of septum (r = -0.472; p = 0.020), and mitral inflow early-to-late diastolic wave ratio (r = 0.592; 
p = 0.002) in TM group. Conclusion: Early diagnosis and treatment of myocardial iron overload are likely to prevent the mortality in pa-
tients with established ventricular dysfunction. Since NT-proBNP levels were not significantly increased in documented left ventricular 
(LV) diastolic dysfunction, this factor may not be sensitive for the detection of latent LV diastolic dysfunction in the early stages of disease 
progression.
©  2020 Polish Society of Hematology and Transfusion Medicine, Insitute of Hematology and Transfusion Medicine. Published by Sciendo. 
All rights reserved.
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Introduction
Impaired synthesis of  β-globin chain is called  β-thalassemia, which is 
widely spread through the Mediterranean area, Africa, and the Middle 
East [1]. Chronic blood transfusions improve oxygen delivery, suppress 
ineffective erythropoiesis, and prolong survival, but the predictable side 
effect is particularly iron overload [1, 2].
Patients with β-thalassemia intermedia (TI) display similar stigmata of 
ineffective erythropoiesis, but they survive without regular transfusion. 
Tissue iron overload is secondary to excess gastrointestinal absorption 
due to accelerated erythropoiesis [1, 2, 3].
Tissue iron overload, as the most important complication, causes organ 
damage which is fatal if not prevented or effectively treated; thus, it 
can be a major focus of management [4]. The leading cause of death 
is cardiac iron overload in patients with β-thalassemia major (TM) and 
TI, which is associated with cardiac dysfunction and also usually with 
chronic cardiac failure [4, 5].
Serum ferritin assay is a simple way for evaluating cardiac risk; this 
inexpensive widely available measurement has also limited usefulness 
in iron load assessment [5–9]. Cardiac iron uptake and toxicity may 
occur despite apparently adequate total body iron balance [10, 11, 12]. 
Electrocardiography and echocardiography signs of toxicity do not 
appear until severe cardiac iron deposition has occurred [9, 13]. 
Cardiac toxicity is often insidious; less than half of the patients with 
β-thalassemia have detectable cardiac iron, though many of them are 
asymptomatic [14, 15].
Noninvasive T2* magnetic resonance imaging (MRI) assessment can 
reliably detect subclinical cardiac iron concentrations and can predict 
the risk of subsequent cardiac dysfunction [10, 13]. Cardiac T2* MRI 
hopefully provides a longer treatment window for iron overload-induced 
cardiomyopathy. It is also possible to identify early onset systolic 
dysfunction and intensive chelation requirement and prevention of 
mortality associated with overt heart failure [10, 16, 17, 18].
N-terminal pro B-type natriuretic peptide (NT-proBNP) is secreted by the 
heart ventricles in response to excessive stretching of cardiomyocyte, 
which decreases blood pressure due to the reduction in systemic 
vascular resistance [19, 20]. Both B-type natriuretic peptide (BNP) and 
NT-proBNP levels are also typically increased in left ventricular (LV) 
dysfunction with or without symptoms [21]. They have developed as 
sensitive biomarkers for screening, diagnosis, treatment, and prognosis 
of heart failure [22, 23, 24]. These biomarkers levels are significantly 
increased in obvious LV diastolic dysfunction, while NT-proBNP level 
seems to have better predictive value in detecting latent LV diastolic 
dysfunction in TM patients [25, 26, 27].
Survival of β-thalassemia patients with heart failure can be dramatically 
improved by early diagnosis of LV diastolic dysfunction and 
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intensification of iron chelation therapy. Thus, we decided to investigate 
the association of NT-proBNP level with echocardiographic findings of 
asymptomatic LV diastolic dysfunction, T2* MRI’s subclinical cardiac 
iron concentrations assessment, and serum ferritin level.
Patients and methods
Study design and patients
This is a cross-sectional case–control study on TM and TI patients, 
who had been registered in thalassemia ward, affiliated to Shiraz 
University of Medical Sciences, from January 2015 to December 2015.
We enrolled 41 TM patients who had been under regular follow-up and 
received regular blood transfusion every 3–4 weeks before the age of 2 
in order to maintain the hemoglobin levels above 9.5 g/dL. All patients 
received iron chelation therapy before the age of 4. In addition, 41 TI 
patients who have occasionally transfused and under regular follow-up 
were enrolled in this study. Only 15 patients (33%) from TI group were 
under regular iron chelation therapy.
Furthermore, all enrolled patients had clinical and hematological 
data records including regular vital signs and growth measurements, 
duration and types of iron chelator, regular cardiovascular assessment 
such as cardiologist consultation, and echocardiography.
Similarly, 41 healthy individuals (HI) as control group without 
positive history of cardiovascular disease and clinical or paraclinical 
cardiovascular evidence were randomly selected from day clinic visitors.
This study protocol was approved by the institutional ethics committee 
and all enrolled patients and/or guardians signed written informed 
consent.
Clinical and biochemical variables
We recorded mean of hemoglobin level during last 6 months, 
mean serum ferritin level in last year, the latest renal function tests 
(blood urea nitrogen and creatinine), liver function tests (alanine 
aminotransferase, aspartate transaminase, alkaline phosphatase, 
albumin, total bilirubin, and direct bilirubin), uric acid of case groups 
(TM and TI patients), and serum level of NT-proBNP of cases (TM 
and TI patients) and control groups.
NT-proBNP measurements were performed with Siemens competitive 
enzyme immunoassay kit (Siemens healthcare diagnostics, Marburg, 
Germany). As a general guideline, 90% of young healthy adults have 
NT-proBNP < 70 pg/mL [28].
T2* MRI
T2* MRI was performed by Siemens 1.5 Tesla (T) MRI (Siemens 
Healthcare GmbH, Germany). Result showing > 20 ms indicates no 
significant iron loading, 10–19 ms indicates mild-to-moderate iron 
loading, and < 10 ms indicates severe cardiac iron loading associated 
with severe LV dysfunction [10].
Echocardiography mode
Echocardiography was performed by Mindray DC7 (China, Shanghai) 
echocardiography machine using a 3 MHz probe. To evaluate systolic 
and diastolic functions, all M-mode, two-dimensional (2D), Doppler, and 
pulse tissue Doppler echocardiographic measures were performed by 
a cardiologist in left lateral decubitus position.
Statistical analysis
All tests were performed using SPSS 21 software package (SPSS, 
Chicago, IL). Data were presented as mean, standard deviation, 
and percentage. Normality of data was checked by Kolmogorov-
Smirnov test. Comparison of continuous variables between the three 
groups was determined by Student’s t-test and Mann-Whitney U test 
as appropriate. Chi-squared test was used to compare qualitative 
variables between two or more groups of patients. One-way analysis 
of variance (ANOVA) was used to assess the differences among ≥ 3 
consecutive groups, and post hoc adjustments for multiple comparisons 
were assessed using Bonferroni’s method. Correlation of NT-proBNP 
with quantitative parameters was estimated using Pearson correlation 
test. The p-value < 0.05 was considered to be statistically significant.
Result
Clinical and laboratory findings
Mean age of the patients was 26.3 ± 7.5 years (ranged 8–40 years) 
including 35 females and 6 males in TM group, 21 females and 
20 males in TI group, and mean age of HI group was 28.6 ± 11.6 
(ranged 8–35 years) including 8 females and 33 males. There were 
no significant age differences among the three groups (p > 0.05).
The highest mean serum ferritin level was found in TM, then TI, and 
the least in HI with significant difference between groups (p < 0.001, 
Tab. I).The mean serum NT-proBNP level in all group was in 
Table I. The mean of ferritin, T2*MRI, and NT-proBNP in TI, TM, 
and HI groups
95% CI
Mean ± SDParameters (N)
Lower–Upper
Ferritin
322.9–490.9403.7 ± 273.7TI (37)
1658.5–28402141.2 ± 1922.1TM (41)
71.6–101.486.8 ± 28.2HI (14)
834.2–1496.81129.8 ± 1580Total (92)
T2* MRI
29.3 ± 37.933.1 ± 12.5TI (33)
21.0 ± 30.225.4 ± 14.7TM (38)
NDNDHI (ND)
26 ± 32.429 ± 14.1Total (71)
NT-proBNP
20.1–101.145.8 ± 61.6TI (40)
13.9–24.217.8 ± 17.1TM (39)
12–13.912.9 ± 1.7HI (14)
21.5–39.629.1 ± 44.1Total (93)
ND – not done; TI –  β-thalassemia intermedia; TM –  β-thalassemia major; HI – healthy 
individual 
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normal range, but the highest was found in TI group with significant 
difference between two other groups (TM and HI) (p = 0.008, Tab. I). 
No statistical difference was detected between TM and HI groups. 
Only three patients in TI group had NT-proBNP > 70 pg/mL.
Echocardiographic parameters
Mean of ejection fraction (EF) was not different in three groups 
(EF in TM: 71%, EF in TI: 70%, and EF in HI: 71%; p = 0.8). Five 
patients had systolic dysfunction (EF < 55%), four patients in TM 
group, and one patient in TI group. None of these cases had T2* MRI 
< 20 or high NT-proBNP level.
TI group had statistically higher mean values for LV internal 
dimension in diastole (LVIDd), end diastolic LV volume (EDV), LV 
internal dimension in systole (LVIDs), and stroke volume (SV) rather 
than other two groups (TM and control have no difference in M-mode 
data) (Tab. II). Interestingly, abnormal LVIDd that indicated dilated LV 
(LVIDd > 5.6) had the highest prevalence in TI group (8 cases out of 
total 9 cases).
The group with high LVIDd (LVIDd > 5.6) had higher NT-proBNP 
level (79.7 vs. 20.4 with p < 0.001) but not statistically different ferritin 
level (p = 0.06). Results of T* MRI were >20 ms in both groups with 
borderline difference (34.2 in high LVIDd vs 28.4 in normal LVIDd,
 p = 0.043).
Diastolic function evaluation
No statistically difference was seen between three groups in mean 
of E/A ratio (p = 0.51) or EaM/AaM (p = 0.38). Based on mitral inflow, 
Doppler finding (5.6%) showed reverse E/A ratio in only three 
patients and four patients (7.4%) showed E/A ratio > 2. Data of Date 
of tissue Doppler imaging (TDI) showed more diastolic impairment 
(20.8% reverse EaM/AaM ratio). None of the patients had restrictive 
pattern in Doppler plus TDI finding or based on E/Ea ratio > 15. Due 
to low number of diastolic impairment, comparison between different 
groups was not meaningful.
Correlation analysis
Between biochemical marker and echocardiographic finding, 
only NT-proBNP had correlation with LVIDd (r = 0.415, p = 0.002) 
and EDV (r = 0.458, p = 0.001). Ferritin has no correlation with 
echocardiographic finding (Tab. III). T2* MRI had weak reverse 
correlation with ferritin level (r = -0.384, p = 0.001). Interestingly, T2* 
MRI has no correlation with the result of echocardiographic finding, 
2D and Doppler index, and TDI (Tab. III).
Iron overload state
In TM group, 39.5% had iron overloading (T2* MRI < 20 ms) vs. 
6.1% of TI group. Serum ferritin was statistically different between 
these groups with cardiac iron load studied using MRI (ferritin level: 
4217 ± 2177, 2280 ± 2569, and 920 ± 912 for severe, mild, and no 
iron load, respectively; p = 0.001) (Tab. IV). Other factors such as 
age, NT-proBNP level, and echocardiographic data were not different 
in these groups with cardiac iron loading.
Table II. Descriptive values and comparison of echocardio-
graphic findings in TI, TM, and HI groups
Parameters N Mean ± SD p
IVSd TI 18 1.0 ± 0.19
0.209
TM 22 1.0 ± 0.32
HI 14 1.2 ± 0.22
Total 54 1.1 ± 0.26
LVIDd TI 18 5.6 ± 0.61
<0.001
TM 22 4.8 ± 0.57
HI 14 4.5 ± 0.48
Total 54 5.0 ± 0.71
LVPWd TI 18 1.0 ± 0.18
0.368
TM 22 0.9 ± 0.27
HI 14 0.98 ± 0.21
Total 54 0.96 ± 0.23
EDV TI 18 157.2 ± 39.3
<0.001
TM 22 110.9 ± 28.8
HI 14 95.7 ± 23.9
Total 54 122.3 ± 40.2
IVSs TI 18 1.4 ± 0.24
0.378
TM 22 1.3 ± 0.21
HI 14 1.5 ± 0.37
Total 54 1.4 ± 0.27
LVIDs TI 18 3.2 ± 0.47
0.007
TM 22 2.8 ± 0.67
HI 14 2.6 ± 0.51
Total 54 2.9 ± 0.61
LVPWs TI 18 1.2 ± 0.22
0.321
TM 22 1.0 ± 0.25
HI 14 1.2 ± 0.22
Total 54 1.1 ± 0.24
ESV TI 18 265.8 ± 937.7
0.330
TM 22 33.2 ± 19.6
HI 14 26.6 ± 12.1
Total 54 109.0 ± 542.9
SV TI 18 112.5 ± 29.7
<0.001
TM 22 77.7 ± 19.4
HI 14 69.0 ± 18.4
Total 54 87.0 ± 29.3
EF TI 18 70.1 ± 10.4
0.835
TM 22 71.5 ± 11.3
HI 14 72.4 ± 9.9
Total 54 71.3 ± 10.55
IVSs – interventricular septal thickness in systole; LVIDd – left Ventricular Internal dimen-
sion in diastole; EDV – end-diastolic left ventricular volume; IVSd – interventricular septal 
thickness in diastole; LVIDs – left ventricular internal dimension in systole; LVPWd – left ven-
tricular posterior wall thickness in diastole; LVPWs – left ventricular posterior wall thickness 
in systole; ESV – end systolic left ventricular volume; SV – stroke volume; EF –  ejection 
fraction; FS – fractional shortening
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Table III. Correlation analysis between biochemical marker and echocardiographic findings
Parameters Ferritin T2* MRI NT-proBNP LVIDd EDV ESV E/A ratio mitral Ea/Aa ratio
Ferritin Pearson 1 -0.368** -0.099 0.154 0.130 0.038 0.113 0.043
P 0.002 0.355 0.270 0.352 0.788 0.418 0.758
N 92 70 89 53 53 53 54 53
T2* MRI Pearson -0.368** 1 0.111 0.193 0.185 0.093 0.315 -0.044
P 0.002 0.366 0.267 0.287 0.597 0.061 0.804
N 70 71 68 35 35 35 36 35
NT-proBNP Pearson -0.099 0.111 1 0.415** 0.458** 0.026 -0.115 -0.062
P 0.355 0.366 0.002 0.001 0.853 0.408 0.658
N 89 68 93 53 53 53 54 53
LVIDd Pearson 0.154 0.193 0.415** 1 0.994** 0.094 0.027 -0.124
P 0.270 0.267 0.002 0.000 0.500 0.847 0.377
N 53 35 53 54 54 54 54 53
EDV Pearson 0.130 0.185 0.458** 0.994** 1 0.083 0.012 -0.141
P 0.352 0.287 0.001 0.000 0.548 0.933 0.313
N 53 35 53 54 54 54 54 53
ESV Pearson 0.038 0.093 0.026 0.094 0.083 1 0.093 0.358**
P 0.788 0.597 0.853 0.500 0.548 0.502 0.009
N 53 35 53 54 54 54 54 53
E/A ratio mitral Pearson 0.113 0.315 -0.115 0.027 0.012 0.093 1 0.076
P 0.418 0.061 0.408 0.847 0.933 0.502 0.586
N 54 36 54 54 54 54 55 54
Ea/Aa ratio Pearson 0.043 -0.044 -0.062 -0.124 -0.141 0.358** 0.076 1
P 0.758 0.804 0.658 0.377 0.313 0.009 0.586
N 53 35 53 53 53 53 54 54
**Correlation is significant at the 0.01 level (two-tailed); NT-proBNP – N-terminal pro B-type natriuretic peptide; LVIDd – left Ventricular Internal; dimension in diastole; EDV – end-diastolic 
left ventricular volume; ESV – end-systolic left ventricular volume
Table IV. Ferritin, age, NT-proBNP level, and echocardiographic data in different categories of iron overload according to T2* MRI
Parameters T2* MRI category N
95% confidence interval for mean
p 
Lower bound Upper bound
Ferritin < 10 ms 6 1932.5 6502.1 0.001
≥ 10 ms and < 20 ms 11 553.8 4006.6
≥ 20 ms 53 668.9 1172.0
Total 70 1009.4 1824.1
NT-proBNP < 10 ms 6 -15.9 74.3 0.972
≥ 10 ms and < 20 ms 10 9.1 44.7
≥ 20 ms 52 22.0 36.2
Total 68 22.3 35.2
EF < 10 ms 2 29.5 121.0 0.127
≥ 10 ms and < 20 ms 6 75.4 84.3
≥ 20 ms 27 66.6 75.0
Total 35 69.1 76.1
EDV < 10 ms 2 37.9 249.2 0.255
≥ 10 ms and < 20 ms 6 71.5 137.4
≥ 20 ms 27 116.6 149.6
Total 35 115.0 142.6
Age < 10 ms 6 23.3 31.2 0.920
≥ 10 ms and < 20 ms 11 20.3 31.3
≥ 20 ms 54 24.2 28.3
Total 71 24.5 28.0
E/A ratio mitral < 10 ms 2 -0.09 2.95 0.802
≥ 10 ms and < 20 ms 7 0.98 1.73
≥ 20 ms 27 1.30 1.65
Total 36 1.30 1.59
Ea/Aa ratio < 10 ms 2 -3.62 6.27 0.542
≥ 10 ms and < 20 ms 7 1.38 2.18
≥ 20 ms 26 1.44 1.88
Total 35 1.49 1.84
NT-proBNP – N-terminal pro B-type natriuretic peptide; EF – ejection fraction; EDV – end-diastolic left ventricular volume
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Discussion
This is a cross-sectional study on patients with β-thalassemia 
syndrome and age and gender-matched healthy controls. In this 
study, the NT-proBNP and serum ferritin levels, systolic and diastolic 
functions of the LV on standard Doppler and pulsed Doppler tissue 
imaging, and T2* MRI results in β-thalassemia patients were 
compared with each other and with HI.
In this study, serum ferritin level was significantly higher in the TM 
group compared with TI and HI groups, and statistically significant 
between patients and HI group. Higher ferritin level was due to 
suboptimal chelation therapy in these patients [29]. Our study 
showed more advance iron loading class in cardiac MRI associated 
with higher level of serum ferritin although there is no linear 
correlation with cardiac MRI index and serum ferritin. This study also 
showed that biochemical markers (ferritin and NT-proBNP) are weak 
indicators of iron loading state and they cannot predict level of iron 
loading. NT-proBNP has weak correlation with cardiac MRI index but 
it cannot predict iron overloading even in severe case of cardiac iron 
overload (mean NT-proBNP 29.1, 26.9, and 29.1 for severe, mild, 
and no iron load in T2* MRI; p = 0.9) and should not be used as 
a marker of cardiac iron load.
Systolic function is a nonsensitive and nonspecific marker of cardiac 
iron loading which was confirmed in this study and other studies. Even 
severe iron loading (T2* MRI < 10 ms) may be present with good 
LV systolic function, iron overload appears to mediate the impaired 
diastolic function leading to stiffness of the myocardial wall but LV 
systolic function preserves normal [29]. Diastolic dysfunction was not 
common in this study and we had no correlation between cardiac iron 
state and echocardiographic diastolic function parameters. It seems 
that these parameters are not sensitive to detect iron overloading 
(only one of diastolic dysfunction cases had abnormal T2*MRI). 
Therefore, echocardiography is neither sensitive nor specific for 
diagnosis of cardiac iron overload state.
In this study, most of the cases with abnormal cardiac iron load 
belong to TM group (88% of all cases with cardiac MRI < 20 ms). 
This group had highest ferritin level but interestingly they had better 
echocardiographic marker than TI group. In addition to less serum 
ferritin in TI, these patients had more LV dilation (44% in TI vs. 4% 
in TM) and LV diastolic dysfunction was more common in TI group 
(16.6% in TI vs. 9% in TM).
The end diastolic LV volume, diastolic interventricular septal 
thickness, the LV posterior wall thickness, SV, and the end systolic 
volume were statistically higher in TI group compared with TM and HI 
groups. All of these indices, which are indicative of increased cardiac 
load, may affect chronic anemia in TI paxtients. Similar observations 
by Amoozgar et al. showed that peak systolic velocity of the posterior 
wall was significantly higher in TI compared with controls (p < 0.05) 
[30].
The tricuspid inflow diastolic and mitral wave velocities were 
significantly higher in TI group. Compared with TM and HI groups, 
the LV diastolic indices of TI showed higher early LV diastolic filling, 
and higher E/A ratio in TM suggested restrictive diastolic pattern and 
stiff myocardial wall. These findings are confirmed from the study by 
Yaprak et al. [31].
Tissue Doppler study showed that the mitral annulus systolic velocity 
was statistically significant between TI and HI groups. The mitral 
annulus early diastolic velocity was significantly higher in thalassemia 
patients. The mitral annulus late diastolic velocity was significantly 
higher in TI but the study by Amoozgar et al. showed that pulse tissue 
Doppler of the lateral mitral annulus had not significantly changed in 
TI compared with control [30].
The systolic velocity of septum was significantly higher in TI group 
compared with TM and HI, which may be due to the effect of chronic 
anemia on intermedia patients. Higher and statistically significant 
tricuspid annulus systolic velocity and inflow early and late diastolic 
velocity in β-thalassemia patients compared with control indicated 
anemia and hyperdynamic state. The findings by Amoozgar et al. [30] 
showed that the peak systolic velocity of the septum and the tricuspid 
annulus had increased significantly in TI patients.
The mean serum NT-proBNP level, as an indicator of asymptomatic 
LV dysfunction, was higher in thalassemia group than control 
group. However, there was near to statistically significant difference 
between TI and control, and statistically significant differences also 
exist between TI and TM groups which may be due to the effect 
of irregular transfusion on increased cardiac volume and pressure 
overload in TI patients. Özyörük et al. [32] and Eghbali et al. [33] 
found that NT-proBNP levels were significantly higher in thalassemia 
patients in comparison with normal subjects.
In this study, the serum level of proBNP in TM and TI in the absence of 
overt heart failure was normal with no correlation with E/Eam ratio, but 
in a report by Kremastinos et al. [34] patients with TM with no heart 
failure had higher NT-proBNP and E/Eam ratio compared with controls 
with positive correlation between both variables. It was also found 
that NT-proBNP serum level significantly increased in patients with 
documented LV diastolic dysfunction [34]. This difference between 
studies may be due to better chronic care in our patients.
We found that cardiac T2*MRI did not have statistically significant 
relationship with serum ferritin or NT-proBNP level, although there 
was significant difference between β-thalassemia patients and control 
group. This may indicate that iron status is an unreliable parameter for 
management of cardiologic complication in β-thalassemia patients. 
Similar observations were reported by Anderson et al. [10]. We may 
need a large cohort of β-thalassemia patients to study carefully 
and closely the relationship between cardiac T2* MRI and serum 
NT-proBNP level.
Although we could not find significant correlation between M-mode 
and T2* MRI index in TM and TI, correlation between cardiac T2* MRI 
and Doppler echocardiography indices in TI may be explained by the 
effect of irregular transfusion in TI patients which affects LV function.
Although mean serum proBNP level was higher in TI compared with 
TM and control groups, myocardial iron content cannot be predicted 
from serum proBNP. Early diagnosis and treatment of myocardial iron 
overload is likely to prevent the mortality in patients with established 
ventricular dysfunction.
Since proBNP levels were not significantly increased in documented 
LV diastolic dysfunction, this factor may not be sensitive for 
detection of latent LV diastolic dysfunction in early stages of disease 
progression.
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